Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Zevra Therapeutics is a rare disease-focused biopharmaceutical company commercializing MIPLYFFA (arimoclomol) for Niemann-Pick Disease Type C and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders. The company operates in ultra-orphan indications with limited patient populations (estimated 3,000-5,000 NPC patients globally), generating revenue from specialized distribution channels while maintaining high cash burn for clinical development programs including KP1077 for idiopathic hypersomnia.
Generates revenue through ultra-orphan drug pricing models with annual treatment costs typically exceeding $300,000-$500,000 per patient. Revenue depends on patient identification, diagnosis rates, and payer reimbursement approval through specialty pharmacies and buy-and-bill models. Gross margins of 68.6% reflect manufacturing efficiency offset by specialty distribution costs. Pricing power derives from lack of therapeutic alternatives in NPC and limited competition in urea cycle disorders, though small addressable markets cap absolute revenue potential.
MIPLYFFA commercial uptake metrics - new patient starts, persistence rates, and quarterly prescription volumes in NPC population
KP1077 regulatory milestones - FDA Complete Response Letter resolution, potential approval timing for idiopathic hypersomnia indication with estimated 37,000 US patients
Clinical trial readouts for pipeline assets including potential label expansions or new indications
Cash runway updates and financing events - equity raises, debt facilities, or partnership announcements given negative $100M+ annual cash burn
Payer coverage decisions and reimbursement approvals for MIPLYFFA affecting revenue trajectory
Ultra-orphan market size constraints - NPC affects estimated 3,000-5,000 patients globally, fundamentally limiting revenue ceiling regardless of market penetration
Regulatory pathway complexity for rare diseases requiring long-term safety studies and post-marketing commitments with ongoing costs
Gene therapy and emerging modality competition potentially offering curative approaches versus chronic symptomatic management
Payer scrutiny intensifying on ultra-orphan drug pricing with potential legislative action on specialty pharmaceutical costs
Limited barriers to entry in small molecule rare disease space - generic sodium phenylbutyrate alternatives exist for OLPRUVA indication
Competitive clinical programs targeting idiopathic hypersomnia including established narcolepsy treatments being repositioned
Larger biopharmaceutical companies with superior commercial infrastructure entering rare disease markets through M&A
Cash burn of $100M+ annually with current ratio of 8.62x suggesting 2-3 years runway at current burn rate, requiring future financing
Equity dilution risk from future capital raises given pre-profitability status and limited non-dilutive funding options
Revenue concentration risk with two commercialized products serving small patient populations vulnerable to adverse events or safety signals
low - Rare disease treatments for life-threatening conditions exhibit minimal demand elasticity regardless of economic conditions. Patient populations are medically driven rather than discretionary, with payer coverage through commercial insurance and Medicaid insulating from consumer spending cycles. However, state Medicaid budget pressures during recessions can delay reimbursement approvals.
Rising rates negatively impact valuation multiples for pre-profitable biotech as discount rates increase on future cash flows. Higher rates increase cost of capital for future equity raises needed to fund operations given $100M+ annual cash burn. Debt financing becomes more expensive though company maintains modest 0.47x debt/equity ratio. Rate environment affects M&A likelihood as strategic acquirers face higher financing costs.
Moderate - Company depends on access to capital markets for ongoing operations with negative operating cash flow. Tightening credit conditions reduce availability of venture debt facilities and increase dilution from equity raises. Investment-grade payer mix (commercial insurance, Medicare) provides revenue stability, but Medicaid reimbursement timing sensitive to state budget constraints during credit stress.
growth - Attracts speculative biotech investors focused on binary regulatory catalysts and rare disease commercial potential. Small market cap ($500M) and negative cash flow profile appeal to venture-style investors willing to accept high risk for potential multi-bagger returns on successful drug approvals. Not suitable for value or income investors given lack of profitability and dividends.
high - Biotech stocks with binary regulatory events exhibit elevated volatility around FDA decisions, clinical data releases, and financing announcements. Small float and limited institutional ownership amplify price swings. Historical volatility likely exceeds 60-80% annualized given pre-revenue/early commercial stage and event-driven catalyst calendar.
